Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 3.38 as of 2026-10-06T15:11:54.409Z.
Consensus retrieved: 2026-10-06T11:08:46.262Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:11:54.409Z.
Quote observation: 2026-10-06T15:10:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b57bdb6cebd2fc5d726de3303ac3337ac80931875060aa84c0ac08143d0f88af
Forward PE Ratio (3.38) = Dated Quote Price ($5.95) / Consensus Forward EPS ($1.76)
FORWARD PE RATIO
3.38
SECTOR MEDIAN · HEALTHCARE
19.19
median of 165 covered companies
CURRENT VS SECTOR MEDIAN
-82.39%
vs the sector median at left
Embecta Corp.
Market Cap
$353.21M
Forward PE Ratio
3.38
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Embecta Corp. (EMBC) | $353.21M | 3.38 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $356.23M | 36.19 |
| Opus Genetics, Inc. (IRD)vs › | $356.23M | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.37M | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $359.28M | N/A |
| Ocugen, Inc. (OCGN)vs › | $359.46M | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $346.15M | N/A |
| Agenus Inc. (AGEN)vs › | $337.51M | 30.30 |
| Canopy Growth Corporation (CGC)vs › | $375.13M | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $330.92M | N/A |
Trailing P/E
4.0
reported TTM EPS
Forward P/E
3.4
consensus EPS · fiscal year ending 2027-09-30
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $1.76 implies +18.9% EPS growth vs the reported trailing $1.48.
At the dated quote price of $5.95, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-09-30 | $1.76 | $1.75 – $1.77 | 3 | 3.4x |
| 2028-09-30 | $1.95 | $1.53 – $2.48 | 3 | 3.1x |
| 2029-09-30 | $2.96 | $2.95 – $2.97 | 1 | 2.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
